<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intracerebroventricular injection of insulin-like growth factor (IGF)-I has been shown to protect against <z:hpo ids='HP_0001297'>stroke</z:hpo> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>This method of delivery is not practical in human beings, as it requires an operation with risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and other complications </plain></SENT>
<SENT sid="2" pm="."><plain>Intranasal (i.n.) delivery offers a noninvasive method of bypassing the blood-brain barrier to deliver IGF-I to the brain </plain></SENT>
<SENT sid="3" pm="."><plain>This study delineates the window of opportunity for treatment of focal cerebral ischemic damage using i.n </plain></SENT>
<SENT sid="4" pm="."><plain>IGF-I after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>Rats were allowed to survive 7 days after 2 hours of MCAO </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> after 7 days, and neurologic deficit scores from the postural reflex and adhesive tape tests assessing motor-sensory and somatosensory functions, respectively, at 1 to 7 days were used to evaluate the efficacy of i.n </plain></SENT>
<SENT sid="7" pm="."><plain>IGF-I (150 microg) administered at different times after MCAO </plain></SENT>
<SENT sid="8" pm="."><plain>I.n </plain></SENT>
<SENT sid="9" pm="."><plain>IGF-I significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 54%; and 39%; versus control when administered at 2 or 4 hours, respectively, after the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAO (P &lt; .05) and improved motor-sensory and somatosensory functions (P &lt; .05) when administered 2 hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAO </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, treatment with i.n </plain></SENT>
<SENT sid="11" pm="."><plain>IGF-I at 2, 4, or 6 hours after MCAO decreased apoptotic cell counts by more than 90%; in the hemisphere ipsilateral to the occlusion </plain></SENT>
<SENT sid="12" pm="."><plain>I.n </plain></SENT>
<SENT sid="13" pm="."><plain>IGF-I is a promising treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo> with a therapeutic window of opportunity for up to 6 hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>This noninvasive method provides a simpler, safer, and potentially more cost-effective method of delivery than other methods currently in use </plain></SENT>
</text></document>